ReviewJournal of ophthalmology2026
Ophthalmological Manifestations of Hereditary Amyloidosis due to Transthyretin: A Systematic Review.
Review in Journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ophthalmological Manifestations of Hereditary Amyloidosis due to Transthyretin: A Systematic Review.Journal of ophthalmology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Amyloidosis involves the deposition of fibrillar proteins in tissues. Hereditary transthyretin amyloidosis (ATTRv), caused by TTR gene mutations, affects various tissues, with ocular involvement in about 10% of patients. Objective: To describe and quantify ocular manifestations in ATTRv through a systematic review. Methods: We reviewed studies on ocular manifestations of ATTRv, including only articles in Portuguese and English, excluding case reports, conference abstracts, and duplicates. Results: Sixteen studies with 1792 patients were analyzed. Vitreous opacities were found in 87.5% of studies (36% frequency). Dry eye was reported in 50% (48.5% frequency) and scalloped pupil in 37.5% (35.9% frequency). Glaucoma had an average frequency of 18.2%, while amyloid deposits in the lens appeared in 37.5% of studies (25.8% frequency). Retinal hemorrhage and vascular tortuosity were less common, and conjunctival lymphangiectasia was found in one study (54.2%). The Val30Met mutation was most prevalent, noted in 92% of cases. No clear link between ocular and systemic symptoms was identified. Conclusion: Vitreous opacities were the most common ocular manifestation, followed by dry eye and scalloped pupil. Further research is needed due to the limited number of representative studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.